Trevena, Inc. to Participate at the Sachs Associates 4th Annual Neuroscience Innovation Forum

Rhea-AI Summary

Trevena, Inc. (TRVN), a biopharmaceutical company specializing in CNS disorders, announced that Dr. Mark A. Demitrack will participate in the 4th Annual Sachs Associates Neuroscience Innovation Forum from April 28-30, 2021. He will present on the Pain, Migraine & Addiction Panel on April 29 at 11:50 a.m. ET. The discussion will be available on demand for registered participants. Trevena has one approved product, OLINVYK™, and a pipeline of four investigational drug candidates addressing critical conditions like migraine and opioid use disorder.

CHESTERBROOK, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark A. Demitrack, M.D., Senior Vice President and Chief Medical Officer, will be participating at the 4th Annual Sachs Associates Neuroscience Innovation Forum taking place from Wednesday, April 28 to Friday, April 30, 2021.

Presentation Details

Format:	Pain, Migraine & Addiction Panel
Date:	Thursday, April 29, 2021
Time:	11:50 a.m. Eastern Time
Presenter:	Mark Demitrack, Senior Vice President and Chief Medical Officer

Trevena’s panel discussion will be available on demand during the conference to registered participants.

About Trevena

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK™ (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s novel pipeline is based on Nobel Prize winning research and includes four differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, TRV045 for epilepsy and chronic neuropathic pain, and TRV027 for acute respiratory distress syndrome and abnormal blood clotting in COVID-19 patients.

For more information, please visit www.Trevena.com.

Investor Contact:
Daniel Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576

PR & Media Contact:
Sasha Bennett
Director
Clyde Group
Sasha.Bennett@clydegroup.com
(239) 248-3409

 

FAQ

What is Trevena's focus in the biopharmaceutical industry?

Trevena focuses on developing and commercializing innovative medicines for patients with central nervous system (CNS) disorders.

When is Dr. Mark A. Demitrack's presentation at the Neuroscience Innovation Forum?

Dr. Mark A. Demitrack's presentation is on April 29, 2021, at 11:50 a.m. Eastern Time.

What topics will be discussed in Trevena's panel presentation?

The panel will cover topics related to pain, migraine, and addiction.

What is OLINVYK™ and what is it used for?

OLINVYK™ (oliceridine) is an injection used for managing acute pain severe enough to require an intravenous opioid analgesic.

What investigational drug candidates is Trevena developing?

Trevena is developing TRV250 for migraine, TRV734 for opioid use disorder, TRV045 for epilepsy and neuropathic pain, and TRV027 for COVID-19 related conditions.